Express News | SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics to Present at INNODIA Annual Meeting
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed
SAB Biotherapeutics Announces Clinical Partnership With Naval Medical Research Center to Advance Potential Influenza Treatment
SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing
SAB Biotherapeutics Announces Executive Leadership Change
SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing
SAB Biotherapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developin
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human anti-thymocyte
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'SAB Biotherapeutics Is Pursuing IND and CTA Filings With U.S. FDA and EMA in 2024 to Clinically Advance Development of SAB-142 Into Phase 2b Study'
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'SAB Biotherapeutics Is Pursuing IND and CTA Filings With U.S. FDA and EMA in 2024 to Clinically Advance Development of SAB-142 Into Phase 2b Study'
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'First Subject Has Been Dosed in the First-in-man Phase 1 Clinical Study of SAB-142, the First Fully-human Anti-thymocyte Immunoglobulin (ATG)'
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'First Subject Has Been Dosed in the First-in-man Phase 1 Clinical Study of SAB-142, the First Fully-human Anti-thymocyte Immunoglobulin (ATG)'
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Announces Commencement Of The HUMAN Phase I Clinical Trial With SAB-142, A Potential Disease-Modifying Treatment For Type 1 Diabetes
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Announces Commencement Of The HUMAN Phase I Clinical Trial With SAB-142, A Potential Disease-Modifying Treatment For Type 1 Diabetes
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a fully-hum
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditionsParticipating investors include Sessa Capital, BVF Partners, RTW Investments, Marshall
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors Received approval by the Human Research Ethics Committee (HREC) to commence a First-in-Human Phase 1
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
SIOUX FALLS, S.D., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), today announced that Michael G. King Jr. has been named Chief Financial Officer. SAB is a clinical-stage
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
Australian Human Research Ethics Committee (HREC) grants approval for SAB to begin first-in-human Phase 1 clinical study of SAB-142, the first fully human anti-thymocyte immunoglobulin (ATG) SAB-142 directly targets
No Data